API
< Back to situations

[ORGANIZATION]

Retatrutide

Featured in 17 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

343 clusters · 1318 sources · last updated

Latest: GLP-1 medications linked to weight regain and hair loss

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt

[ACTIVE] [HEALTH] [US] [BR] [CN]

Retatrutide development and regulatory actions

7 clusters · 36 sources · last updated

Latest: Eli Lilly experimental drug retatrutide shows promise for knee osteoarthritis

Retatrutide, an investigational synthetic peptide developed by Eli Lilly, is being studied for its metabolic potential in managing food regulation, sugar, and weight. As a triple receptor agonist, it mimics natural gut a

[QUIET] [HEALTH] [US] [AR] [CA]

Eli Lilly EloraTZP and retatrutide obesity drug clinicals

4 clusters · 38 sources · last updated

Latest: Eli Lilly's retatrutide outperforms Ozempic in weight loss trial

Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data indicates the combination tar

Also covered in